Technical operation specification for tissue matching and immune monitoring techniques in renal transplantation (2019 edition)
-
摘要: 为了进一步规范肾移植组织配型及免疫监测技术操作, 中华医学会器官移植学分会组织器官移植学专家从组织配型基本技术、配型方法、群体反应性抗体、供体特异性抗体、受者免疫监测等方面, 制订本规范。
-
关键词:
- 肾移植 /
- 人类白细胞抗原 /
- 主要组织相容性复合体 /
- 群体反应性抗体 /
- 供体特异性抗体 /
- 补体依赖淋巴细胞毒性试验 /
- 酶联免疫吸附试验 /
- 免疫监测
-
表 1 HLA Ⅰ类抗原氨基酸残基配型标准
Table 1. The matching standard type of amino acid residues of HLA Ⅰ antigen
Res M分组 抗原特异性 A1(R114) A1, A3, A11, A29, A36 A2(K127) A2, A23, A24, A68, A69 A10/A19(Q114) A25, A26, A34, A66, A19(A31, A32, A33, A74), A43 B5/B8(F67) B5(B51), B35, B53, B78, B8, B57 B7(A71-D74) B7, B22(B54, B55, B56), B27, B42, B46, B67 B8(T69-S77) B8, B14(B64, B65), B16(B39), B78 B12(T41) B12(B44, B45), B13, B21(B49, B50), B40(B60, B61), B41, B47 B17/B63(S70) B17(B57, 58), B63, B59 Bw4(R83) A9(A23, A24), A25, A32, B5(B51, B52), B12, B13, B17(B57, B58), B21(B49), B27, B37, B38, B47, B53, B59, B63, B77 Bw6(N80) A11, B7, B8, B18, B14(B64, B65), B15(B62, B75, B76, B78), B16(B39), B22(B54, B55, B56), B35, B40(B60, B61, B48, B4005), B41, B42, B45, B46, B50, B67, B70, B71, B72 表 2 HLA Ⅱ类抗原氨基酸残基配型标准
Table 2. The matching standard type of amino acid residues of HLA Ⅱ antigen
Res M分组 抗原特异性 DQ1 DR1(DR10), DR2(DR15, DR16), DR6(DR13, DR14) DQ2 DR3(DR17, DR18), DR7 DQ3 DR4, DR5(DR11, DR12), DR9, DR14 DQ4 DR8, DR18 DRB3 DR3(DR17, DR18), DR5(DR11, DR12)DR6(DR13, DR14) DRB4 DR4, DR7, DR9 DRB5 DR1(DR10), DR2(DR15, DR16) -
[1] APANIUS V, PENN D, SLEV PR, et al. The nature of selection on the major histocompatibility complex[J]. Crit Rev Immunol, 2017, 37(2/3/4/5/6):75-120. DOI: 10.1615/CritRevImmunol.v37.i2-6.10. [2] SINGH SP, MISHRA BN. Major histocompatibility complex linked databases and prediction tools for designing vaccines[J]. Hum Immunol, 2016, 77(3):295-306. DOI: 10.1016/j.humimm.2015.11.012. [3] SOUTH AM, GRIMM PC. Transplant immuno-diagnostics: crossmatch and antigen detection[J]. Pediatr Nephrol, 2016, 31(6):897-905. DOI: 10.1007/s00467-015-3145-z. [4] KRANSDORF EP, PANDO MJ, GRAGERT L, et al. HLA population genetics in solid organ transplantation[J]. Transplantation, 2017, 101(9):1971-1976. DOI: 10.1097/TP.0000000000001830. [5] 龚非力.医学免疫学[M].北京:科学出版社, 2013. [6] 窦肇华, 张远强, 郭顺根, 等.免疫细胞学与疾病[M].北京:中国医药科技出版社, 2004. [7] 赵卫东, 周茂华.实用流式细胞分析技术[M].广州:广东科技出版社, 2000. [8] 王建中.临床流式细胞分析[M].上海:上海科学技术出版社, 2005. [9] SHAHEEN FA. Organ transplantation in Saudi Arabia[J]. Transplantation, 2016, 100(7):1387-1389. DOI: 10.1097/TP.0000000000001295. [10] ALEXANDER SI, CLAYTON PA, CHADBAN SJ. Organ transplantation in Australia[J]. Transplantation, 2017, 101(5):891-892. DOI: 10.1097/TP.0000000000001621. [11] PASCUAL J, ZUCKERMANN A, DJAMALI A, et al. Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation--a review[J]. Transplant Rev (Orlando), 2016, 30(2):85-91. DOI: 10.1016/j.trre.2015.12.002. [12] IDICA A, EVERLY MJ. Donor-specific HLA antibodies: a review of data published in 2016[J]. Clin Transpl, 2016, 32:13-22. [13] WEBER LT. Preexisting anti-HLA donor-specific antibodies in pediatric renal transplant recipients - a new challenge? [J]. Pediatr Transplant, 2017, 21(8). DOI: 10.1111/petr.13085. [14] KARADENIZ ST, AKGUL SU, OGRET Y, et al. Corrected panel-reactive antibody positivity rates for hypersensitized patients in Turkish population with calculated panel-reactive antibody software[J]. Transplant Proc, 2017, 49(3):445-447. DOI: 10.1016/j.transproceed.2017.01.032. [15] LEE N, PARK HS, IN JW, et al. Association of HLA types with non-specific binding of negative control beads in luminex panel reactive antibody (PRA) screening assay[J]. Clin Lab, 2017, 63(1):169-174. DOI: 10.7754/Clin.Lab.2016.160713. [16] HUBER L, LACHMANN N, NIEMANN M, et al. Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients[J]. Transpl Int, 2015, 28(6):710-719. DOI: 10.1111/tri.12533. [17] 刘艳荣.实用流式细胞术[M].北京:北京大学医学出版社, 2010. [18] 吴丽娟.临床流式细胞学检验技术[M].北京:人民军医出版社, 2010. [19] KLAVER Y, KUNERT A, SLEIJFER S, et al. Adoptive T-cell therapy: a need for standard immune monitoring[J]. Immunotherapy, 2015, 7(5):513-533. DOI: 10.2217/imt.15.23. [20] SOLÉ C, LARREA E, DI PINTO G, et al. MiRNAs in B-cell lymphoma: molecular mechanisms and biomarker potential[J]. Cancer Lett, 2017, 405:79-89. DOI: 10.1016/j.canlet.2017.07.020. [21] VOSS M, BRYCESON YT. Natural killer cell biology illuminated by primary immunodeficiency syndromes in humans[J]. Clin Immunol, 2017, 177:29-42. DOI: 10.1016/j.clim.2015.11.004. [22] SAFA K, CHANDRAN S, WOJCIECHOWSKI D. Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects[J]. Drugs, 2015, 75(16):1843-1852. DOI: 10.1007/s40265-015-0487-6. [23] VAN DOESUM WB, ABDULAHAD WH, VAN DIJK MC, et al. Characterization of urinary CD4+ and CD8+ T cells in kidney transplantation patients with polyomavirus BK infection and allograft rejection[J]. Transpl Infect Dis, 2014, 16(5):733-743. DOI: 10.1111/tid.12273. [24] SCHACHTNER T, STEIN M, REINKE P. Sepsis after renal transplantation: clinical, immunological, and microbiological risk factors[J]. Transpl Infect Dis, 2017, 19(3). DOI: 10.1111/tid.12695.
计量
- 文章访问数: 413
- HTML全文浏览量: 352
- PDF下载量: 134
- 被引次数: 0